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Abstract 
Context: Aggressive pituitary tumors (APTs) are characterized by unusually rapid 
growth and lack of response to standard treatment. About 1% to 2% develop metastases 
being classified as pituitary carcinomas (PCs). For unknown reasons, the corticotroph 
tumors are overrepresented among APTs and PCs. Mutations in the alpha thalassemia/
mental retardation syndrome X-linked (ATRX) gene, regulating chromatin remodeling 
and telomere maintenance, have been implicated in the development of several cancer 
types, including neuroendocrine tumors.
Objective: To study ATRX protein expression and mutational status of the ATRX gene in 
APTs and PCs.
Design: We investigated ATRX protein expression by using immunohistochemistry 
in 30 APTs and 18 PCs, mostly of Pit-1 and T-Pit cell lineage. In tumors lacking ATRX 
immunolabeling, mutational status of the ATRX gene was explored.
Results: Nine of the 48 tumors (19%) demonstrated lack of ATRX immunolabelling with 
a higher proportion in patients with PCs (5/18; 28%) than in those with APTs (4/30;13%). 
Lack of ATRX was most common in the corticotroph tumors, 7/22 (32%), versus tumors 
of the Pit-1 lineage, 2/24 (8%). Loss-of-function ATRX mutations were found in all 9 ATRX 
immunonegative cases: nonsense mutations (n = 4), frameshift deletions (n = 4), and 
large deletions affecting 22-28 of the 36 exons (n = 3). More than 1 ATRX gene defect was 
identified in 2 PCs.
Conclusion: ATRX mutations occur in a subset of APTs and are more common 
in corticotroph tumors. The findings provide a rationale for performing ATRX 
immunohistochemistry to identify patients at risk of developing aggressive and 
potentially metastatic pituitary tumors.
Freeform/Key Words:  ATRX (alpha thalassemia/mental retardation syndrome X-linked), aggressive PitNETs, pituitary 
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Pituitary neuroendocrine tumors (PitNETs) (1), tradition-
ally designated as pituitary adenomas, are usually benign 
tumors with indolent, nonaggressive course. Recently, the 
European Society of Endocrinology published criteria that 
define aggressive PitNETs as tumors demonstrating an un-
usually fast growth and/or lack of response to all standard 
treatment modalities including surgery, and radio- and 
pharmacological therapies (2). Pituitary carcinomas (PCs) 
are defined by the presence of noncontiguous craniospinal 
or distant metastases (3). While PCs are rare and consti-
tute only 0.1% to 0.2% of all pituitary neoplasms (4), the 
prevalence of aggressive pituitary tumors (APTs) without 
metastases is less well known. An estimate of 3% has been 
suggested based on indices of increased proliferation and 
extensive p53 staining in tumor specimens from 451 pa-
tients reported to the German Pituitary Tumor Registry (5). 
Little is known about genetic abnormalities driving inva-
sive and metastatic pituitary tumors. Whether they develop 
through malignant progression of benign pituitary tumors 
or occur as de novo malignant tumors caused by early, 
single, or multiple genetic changes predisposing for distant 
dissemination is unknown.
The functioning corticotroph tumors causing Cushing’s 
disease represent less than 5% of the benign, slow-growing 
PitNETs (6, 7). However, they are overrepresented among 
APTs and PCs, where they constitute approximately 30% 
to 40% (8, 9). One suggested explanation for this was a 
lower expression of the cell cycle inhibitor p27 in normal 
corticotroph cells and corticotroph tumors (10); however, 
the mechanisms are still unclear. Silent corticotroph tumors 
are also considered potentially more aggressive according 
to the current World Health Organization classification of 
the pituitary tumors (3), although a recent meta-analysis 
could not identify an increased recurrence rate in this sub-
type (11).
In patients with APTs, genetic abnormalities have pre-
viously only been reported in single sporadic cases, none 
has consistently been found in larger groups of patients 
(12). In a case of clinically nonfunctioning gonadotroph 
carcinoma, a low level of HER2/neu gene amplification 
was demonstrated by using fluorescence in situ hybridiza-
tion and chromogenic in situ hybridization analysis (13). 
The presence of mi-RNAs probably targeting PTEN (phos-
phatase and tensin homolog) and TIMP2 (tissue inhibitor 
of metalloproteinases 2) was reported as potential drivers 
of metastatic growth in a case with a nonfunctioning PC 
(14). A single case of PC was reported in a patient with suc-
cinate dehydrogenase subunit B gene mutation and history 
of paraganglioma (15). Finally, tumor protein p53 muta-
tions in 2 PCs have been described (16).
Alpha thalassemia/mental retardation syndrome 
X-linked (ATRX) interacts with death domain-associated 
protein (DAXX) and the histone H3.3 variant in hetero-
chromatin remodeling and maintenance of telomere struc-
ture and function (17, 18). Inactivation of ATRX or, less 
frequently, DAXX in ATRX/DAXX mutated tumors, leads 
to telomere destabilization and facilitates the process of al-
ternative lengthening of telomeres (ALTs), which results in 
cancer cell immortality (19, 20). Somatic ATRX gene mu-
tations are associated with several different tumor types, 
including astrocytomas in adults (21) and neuroendocrine 
tumors (NETs) such as pancreatic NETs (22, 23), neuro-
blastomas (24), and paragangliomas/pheochromocytomas 
(25, 26). Interestingly, in neuroendocrine tumors, ATRX 
abnormalities seem to predict malignant tumor pheno-
type, being present in high-grade malignant tumors such 
as neuroblastoma (24), or associated with poor prognosis 
and/or metastatic potential, such as in pancreatic NET 
(27), and pheochromocytomas/paraganglioma (26).
We have previously demonstrated normal 
immunohistochemical expression of ATRX protein in 
a large cohort of 246 well-characterized PitNETs local-
ized to the sellar region, including 37 corticotroph tu-
mors. However, 1 of 2 studied pituitary carcinomas (a 
corticotroph carcinoma in a patient with Cushing’s disease) 
did not express the protein due to a large deletion of the 
ATRX gene (28).
In the present study, we aimed to further explore ATRX 
protein expression and mutational status of the ATRX 




Pituitary tumor specimens were obtained from a multicenter 
cohort of 48 patients (15 female, 33 male), with a median 
age 45 (range 16-73 years) at diagnosis. Inclusion criteria 
were at least 1 pituitary surgery and tumor progression des-
pite radiotherapy, and/or while on treatment with dopa-
mine agonists or somatostatin analogues, or metastatic 
disease. Thirty patients had APTs and 18 had PCs with 
cerebrospinal and/or systemic metastases. The median time 
from diagnosis of the pituitary tumor to metastases was 8.5 
(range 1.2-36) years (Table 1). The patients were treated 
at specialized centers in 11 European countries (Belgium, 
Denmark, Finland, France, Hungary, Italy, Norway, Poland, 
Serbia, Sweden, and UK). Patients’ data and tumor char-
acteristics at the first presentation, treatments given, and 
outcome were collected in anonymized standardized ques-
tionnaires filled in by all participating centers.
Information on pituitary tumor size and local extension 
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in 45 and 43 patients, respectively. All but 1 lactotroph 
tumor were macroadenomas at the time of diagnosis. By the 
time of pituitary surgery, invasion of the cavernous sinuses, 
bone and/or brain was evident on MRI in the 39 cases, 
including the single patient who had a microadenoma. Of 
the 48 patients, 39 had more than 1 pituitary surgery, and 
33 more than 2. Forty-six out of the 48 patients had re-
ceived at least 1 radiotherapy. In 1 case, tumor size and ex-
tension were considered too large for radiotherapy, and in 
the second case the reason for not performing radiotherapy 
was not available. No tumor treated with dopamine agon-
ists and/or somatostatin analogues (octreotide, lanreotide, 
pasireotide) was controlled by these medications (Table 1). 
In addition to standardized medical therapy, 34 patients 
had received treatment with chemotherapy, temozolomide 
in 33 including 1 patient with additional bevacizumab, and 
another 1 with an mTOR inhibitor and 2 immune check-
point inhibitors.
Tumors were classified based on the laboratory and clin-
ical signs of pituitary hormone hypersecretion, expression 
of anterior pituitary hormones in the tumor cells, and, in 
the cases of hormone-negative nonfunctioning tumors, by 
their expression of pituitary-specific transcription factors. 
Corticotroph tumors were the most common: 22/48, of 
which 16 were functioning tumors causing Cushing’s dis-
ease. Lactotroph tumors were the second most common, 
n = 15 (Table 1).
The index patient with ATRX mutation has been pre-
viously reported (28) and is also included in the present 
study. Of the 48 patients, 3 had syndromes predisposing for 
pituitary tumors, 1 had MEN1 (29), 1 had Lynch syndrome 
(30), and 1 patient belonged to a kindred with familial pre-
disposition for pituitary tumors, but without MEN1 or 
AIP mutation. In addition, pituitary tumor tissue from a 
corticotroph nonaggressive macroadenoma in a patient 
with Lynch syndrome was investigated. This case was not 
included in the statistical analyses as it did not fulfil the cri-
teria for aggressive tumors.
In 45 patients, at least 1 specimen from pituitary sur-
gery was available for analyses. In the remaining 3 patients, 
there was only specimen from the metastasis. For 7 patients 
with carcinoma, material from both pituitary surgery and 
from metastatic tumor was available. The presence of rep-
resentative tumor tissue was confirmed in hematoxylin and 
eosin stained slides from all specimens.
Immunohistochemical analyses
Immunohistochemistry (IHC), with antibodies towards 
growth hormone (GH), prolactin (PRL), thyrotroph hor-
mone (TSH), adrenocorticotroph hormone (ACTH), 
gonadotroph hormones, follicle-stimulating hormone 
(FSH), and luteinizing hormone (LH), was performed 
at the local IHC laboratories according to the routine 
protocols. Immunohistochemical analysis with antibodies 
towards pituitary-specific transcription factors was per-
formed at Uppsala University Hospital by using anti-SF1 
antibody (Abcam, ab217317), anti-Pit-1 antibody (Novus 
Biologicals, NBP1-92273), and anti-T-Pit antibody (Atlas 
Antibodies, AMAb91409), according to the standard 
protocols.
ATRX protein expression was studied on whole 
sections from formalin-fixed paraffin-embedded tissue 
blocks. For the patients operated on more than once, 
available tissue specimens from multiple surgeries were 
examined. In the majority of cases, IHC was performed 
at Uppsala University Hospital in a DAKO-Autostainer 
Link 48 with heat-induced epitope retrieval at high pH. 
Purified polyclonal anti-ATRX antibody (HPA001906, 
Atlas Antibodies; dilution 1:100; incubation time 20 min-
utes) was used. Specimens from 2 adult astrocytomas, 1 
with ATRX mutation and 1 without ATRX mutation, both 
Table 1. Patient and tumor characteristics in the study 
population
Total APT PC
Total n 48 30 18
Age at diagnosis, year (median, 
range)
45 (16-73) 46.5 (18-73) 42 (16-
69)
Male n (%) 33 (69) 23 (77) 10 (56)
Macroadenomasa 44/45 28/29 16/16
Invasive growtha 39/42 24/27 15/15
No of surgeries (median, range) 3 (1-10) 3 (1-10) 3.5 
(1-8)
No of radiotherapies (median, 
range)
1 (0-4) 1 (0-2) 2 (1-4)
Resistance to DA/ somatostatin 
analogsb
27/27 18/18 10/10
Time to metastases from first 
surgery, year (median, range)
  8.5 
(1.2-
36)
Treatment with cytotoxic drugsb 35/37 21/23 14/14
ATRX negative, n (%) 9 (19) 4 (13) 5 (28)
Tumor subtypes (IHC)    
 Corticotrophc 22 10 12
 Lactotroph 15 12 3
 Somatotroph 4 2 2
 Somato/lactotroph 2 1 1
 TSH/FSH 1 1 0
 Silent Pit 1 positive PitNET 3 3 0
 Null cell 1 1 0
Abbreviations: APT, aggressive pituitary tumor; PC, pituitary carcinoma; DA, 
dopamine agonist; IHC, immunohistochemistry.
aMRI at first tumor presentation in patients with available information.
bIn patents with available information.
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confirmed by using molecular genetic analysis, were used as 
negative and positive controls. In addition, immunolabelled 
endothelial cells served as an internal positive control. Four 
cases from Foch Hospital (Suresnes, France) and a case 
from University Hospital in Copenhagen, Denmark, were 
stained in Ventana Benchmark by using the same antibody 
and according to the locally optimized protocols.
Molecular genetic analysis
Molecular genetic analysis was performed on tumor tissue 
from the pituitary specimen in all nine cases demonstrating 
lack of ATRX immunolabelling. In 2 patients, specimens 
from metastases were also analyzed. If there was more than 
1 specimen from the pituitary surgery, the specimen with 
the most representative tumor tissue was used. In 1 patient, 
a partial lack of ATRX protein labelling was observed in 
the pituitary specimen and a total lack in metastatic tumor 
tissue. In this patient, an attempt was made to microdissect 
tissue and extract DNA separately from ATRX negative 
and positive area of the pituitary tumor. In addition, the 
specimen from metastasis with negative ATRX staining 
was analyzed. All but 1 specimen were examined by a next-
generation sequencing (NGS) panel targeting 20 genes (31) 
related to cancers of the central nervous system as in the 
initial study (28). The proportion of tumor cells exceeded 
70% in all the specimens. One specimen was analyzed 
using an exome-wide sequencing approach.
Next-generation sequencing 
DNA was purified from 10-µm paraffin slides using 
GeneRead DNA FFPE Kit (Qiagen, Germany) according to 
the manufacturer’s instructions. NGS was performed with a 
custom designed central nervous system panel covering the 
entire coding sequence or hotspot regions of 20 genes fre-
quently mutated in brain tumors (32). DNA was quantified 
using an RNase P TaqMan Copy Number Reference Assay 
performed on a QuantStudio 12K Flex Real-Time PCR 
System (Applied Biosystems, Foster City, CA). Libraries 
were prepared in 2 primer pools using the Ion AmpliSeq 
Library Kit Plus and Ion Xpress Barcode Adapters 1–96 Kit 
in 10 µL of reaction volume with 5 ng of template DNA. 
Library quantitation was performed using the Ion Library 
Quantitation Kit. Sample preparation, chip loading, and 
sequencing were performed using Ion Chef and Ion Torrent 
S5 System with Ion S5 Chef solutions, Ion S5 sequencing 
reagents and Ion 530/540 Chip Kits. All Ion products were 
supplied by Ion Torrent/ThermoFisher Scientific, Carlsbad, 
CA, USA. Data analysis, including base calling, quality 
scoring, trimming, demultiplexing, and alignment, was per-
formed using standard Ion Torrent Suite v5.10 workflows. 
BAM alignment files were manually analyzed for alter-
ations in the coding sequences of the 20 genes using Golden 
Helix GenomeBrowse 3.0 (Golden Helix, Bozeman, MT, 
USA). The sequencing experiments included ATRX wild-
type control samples from healthy donors.
One specimen was analyzed using hybridization capture-
based high-throughput NGS platform from Illumina (33).
Ethics approval
The study has been approved by Regional Ethics Committee 
in Uppsala (Dnr 2018/327).
Results
Lack of ATRX protein expression is frequent in 
corticotroph tumors
Nine of the 48 tumors (19%) demonstrated lack of ATRX 
immunolabelling in the tumor cells. Five were carcinomas 
and 7 were corticotroph tumors, representing 32% of all 
corticotroph tumors (7 out of 22). Lack of protein ex-
pression was more common in patients with functioning 
corticotroph tumors (6/16, 38%) than in those with si-
lent corticotroph tumors (1/6, 17%). Of the remaining 2 
ATRX-immunonegative tumors, 1 was a lactotroph APT 
with a fatal outcome, and 1 was a somato-lactotroph car-
cinoma that initially presented as a prolactinoma and sub-
sequently evolved into acromegaly (Table 2).
More than 1 pituitary specimen was available for ana-
lysis in 6 of 7 patients who underwent multiple surgeries. 
In 5 of the 6 patients, all specimens demonstrated lack of 
ATRX in all tumor cells. In 1 patient, the specimen from 
the first surgery could not be assessed, and there was par-
tial lack of ATRX expression in pituitary tumor from the 
second surgery and a total lack in the metastasis. In 5 pa-
tients with PC, specimens from metastases were available in 
4 and demonstrated negative ATRX staining in the tumor 
cells. The remaining 39 pituitary tumors demonstrated in-
tact nuclear ATRX expression.
Examples of PitNETs with normal ATRX staining, 
total lack of immunolabelling and partial negative ATRX 
staining in primary and metastatic tumors are illustrated 
in Fig. 1.
All ATRX-immunonegative tumors harbor loss-
of-function ATRX gene abnormalities
ATRX loss-of-function gene abnormalities were found in all 9 
ATRX-immunonegative tumors (Table 3) (31). Two different 
damaging ATRX mutations with large differences in muta-
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in 2 carcinomas from male patients. One of these 2 tumors 
demonstrated a partial lack of ATRX at IHC. An attempt to 
extract separately DNA from ATRX-immunopositive and 
negative fraction was, however, unsuccessful, as the same mu-
tational status was confirmed in both fractions. Interestingly, 
only the predominant mutation from this pituitary tumor was 
present in the metastasis (6 years later) with a frequency of 
98%, suggesting clonal heterogeneity and evolution of the 
primary tumor (Table  3) (31). Three tumors did not show 
any ATRX single nucleotide variants or small indels, but had 
large, intragenic deletions corresponding to most of the coding 
sequences (22-28 of 36 exons) (Fig. 2A and 2B). One of these 
tumors was the corticotroph tumor previously reported, 
whereas the other 2 were lactotroph and somato-lactotroph, 
respectively. All identified ATRX single nucleotide variants 
and small indels were positioned throughout the coding se-
quence of the ATRX gene (Fig. 2C). In addition to the ATRX 
mutations, 8 out of 9 ATRX-immunonegative tumors had 
other genetic abnormalities: inactivating somatic mutations in 
tumor suppressor genes TP53 (6), PTEN (2), RB1 (1), NF2 
(1), and a homozygous deletion of CDKN2A/B in both pri-
mary tumor and metastasis in 1 patient (Table 3). Recurrent 
copy number variants (CNVs) that were estimated from the 
sequencing data were all gains, and involved chromosomes 5, 
7, 9p21.3 encompassing CDKN2A/B loci as well as the CIC 
locus on 19q.
Discussion
Little is known about genetic abnormalities driving inva-
sive and metastatic growth of PitNETs. Here, we demon-
strate a loss of ATRX protein expression caused by severe 
loss-of-function ATRX gene alterations in almost a fifth of 
highly APTs, with a higher prevalence in PC than in APT, 
and in corticotroph tumors than in other lineage subtypes. 
This indicates that corticotroph tumors are prone to de-
velop ATRX gene abnormalities.
We reported previously normal ATRX expression in 246 
PitNETs localized to the sellar region. However, in 1 female 
patient diagnosed with Cushing’s disease and a pituitary 
macroadenoma at an age of 36 years, we found negative 
ATRX immunolabelling caused by a large deletion of the 
ATRX gene (28). This tumor had progressed over time and 
had become metastatic despite multiple transsphenoidal 
surgeries, pharmacological therapy, and 3 different modal-
ities of radiation therapy. ATRX staining was absent in all 
the tumor specimens including the 1 from the first surgery.
In the present extended study, we demonstrate ATRX 
gene defects in 8 additional patients. Thus, 9 out of 48 
patients (19%) with APTs or carcinomas harbored loss-
of-function ATRX gene alterations, more frequently 
in patients with PC than with APT (28% vs 13%). Five 
out of the total 9 patients with ATRX gene defects had 
carcinomas. Of the 4 APT patients, 2 died due to progres-
sive tumor growth, in another there was a short time from 
the tumor diagnosis to the study end, and in the last patient 
search of metastases was not performed due to advanced 
dementia. Further studies with longer follow-up are needed 
to assess to what extent an initial ATRX defect leads to a 
metastatic disease.
In addition to our previously reported case of ATRX 
mutated corticotroph carcinoma (28), a corticotroph car-
cinoma with an ATRX mutation in combination with 
PTEN and TP53 mutations has been described; however, 
without detailed presentation of genetic data (34).
In a recent study (35), whole exome sequencing of 
18 corticotroph tumors lacking mutations in the USP8 
(ubiquitine specific peptidase 8) gene, mutations that drive 
corticotroph tumors in approximately 50% of patients 
with Cushing’s disease, demonstrated ATRX mutations 
concomitantly with TP53 mutations in 2.  Although de-
tailed clinical data regarding aggressiveness of the 2 ATRX 
mutated tumors were not presented, both were recurrent 
and required surgery on 2 and >3 occasions, respectively, 
and Ki67 proliferative index was increased in 1 of the cases 
(35). Lack of ATRX immunolabelling was recently found 
in 3 lactotroph macroadenomas from a cohort of 42 pedi-
atric PitNETs, but molecular genetic confirmation of the 
ATRX mutations was not provided (36). Recently, ALT 
Table 2. Patient and tumor characteristics in ATRX mutated 
vs intact cases
ATRX mutated ATRX intact
Total n 9 39
Age at diagnosis, year (median, range) 45 (23-72) 45 (16-73)
Male, n (%) 6 (67) 27 (69)
Aggressive pituitary tumors, n (%) 4 (44) 26 (67)
Pituitary carcinomas, n (%) 5 (56) 13 (33)
Tumor subtypes (IHC)   
 Corticotroph (n = 22) 7 15
  PC (n = 12) 4 8
  APT (n = 10) 3 7
 Lactotroph (n = 15) 1 14
  PC (n = 3) 0 3
  APT (n = 12) 1 11
 Somato/lactotroph (n = 2) 1 1
  PC (n = 1) 1 0
  APT (n = 1) 0 1
 Other subtypesa (n = 9) 0 9
  PC (n = 2) 0 2
  APT (n = 7) 0 7
Abbreviations: APT, aggressive pituitary tumor, IHC, immunohistochemistry; 
PC, pituitary carcinoma.
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phenotype has been reported in 3 of 106 PitNETs, 2 were 
recurrent nonfunctioning PitNETs without specification of 
cell linage differentiation, and 1 was a somatotroph tumor 
(37). Two of the 3 ALT-positive PitNETs demonstrated loss 
of ATRX or DAXX at protein level, indicating a homo-
zygous loss of the gene or alternative mechanism of gene 
silencing. However, no ATRX or DAXX mutations were 
identified by sequencing (37).
In patients who had repeated pituitary surgeries in the 
present cohort, an ATRX defect was already present in 
the first removed tumor, though in 1 patient tumor tissue 
from the first surgery was not evaluable. This indicates that 
ATRX abnormalities represent an early genetic event con-
tributing to aggressive behavior and, at least in a subset of 
patients, to metastatic spread. Where material from both 
the pituitary tumor and metastasis was available (n = 4), 
identical patterns of a complete loss of ATRX were seen in 
3, whereas 1 one case, partial loss of ATRX was identified 
in the pituitary tumor and a complete loss in the metas-
tasis. A similar case of a PitNET with ALT-negative pheno-
type in the original tumor, and ALT-positive phenotype and 
a partial loss of ATRX in a recurrent tumor, was recently 
reported (37). These findings suggest that an ATRX mu-
tation may occur, though rarely, in pituitary tumors with 
primarily intact ATRX, contributing to malignant tumor 
progression.
In the ATRX-mutated cases in our cohort, we demon-
strated different loss-of-function ATRX defects including 
nonsense mutations, frameshift indels, and, in 3 cases, large, 
intragenic deletions of almost the whole gene (22-28 of the 
36 exons). Interestingly, large deletions of almost the whole 
ATRX gene have only rarely been reported in other tumor 
Figure 1. Histopathological and immunohistochemical features of PitNETs. Row 1: Hematoxylin eosin staining of a primary pituitary tumor invading 
into the respiratory mucosa (1A) with a total lack of ATRX in tumor cells nuclei both the primary pituitary tumor (1B) and a lymph gland metastasis 
(1C) in a patient with a functioning somato-lactotroph carcinoma. ATRX expression is intact in respiratory epithelium, endothelial cells and lympho-
cytes. Row 2: Hematoxylin eosin staining from the primary pituitary tumor in a patient with a silent corticotroph carcinoma (2A). A partial nuclear 
ATRX-loss in a proportion of cells in the specimen from the second pituitary surgery (2B) and a total ATRX-loss in the metastasis (2C) ATRX expres-
sion is preserved in the nuclei of the endothelial cells. Row 3: Hematoxylin eosin staining of the specimen from the first surgery (3A) and normal 
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types, such as astrocytomas (21, 32), pancreatic NETs (22), 
and pheochromocytomas and paragangliomas (25). Yet, a 
recent study on ATRX alterations in neuroblastoma dem-
onstrated a strong tendency for large, intragenic deletions 
of exons 1-9, encoding the first half portion of the ATRX 
protein (38). In our cohort, there was no predominance of 
a particular type of mutation in carcinomas compared with 
APTs, or in corticotroph compared with Pit-1-lineage tu-
mors. However, the number of mutated cases may be too 
low to make conclusions on a potential genotype–pheno-
type association.
Blood samples or normal tissues from patients were not 
included in the sequencing experiments to test for germline 
mutations. The variant allele frequencies of mutations in 
ATRX reported in this study are in favor of somatic rather 
than germline origin. Furthermore, IHC revealed normal 
ATRX expression in non-neoplastic cells in all the mutated 
specimens, arguing for the somatic origin of the ATRX 
gene defects.
In the present study, we had the opportunity to inves-
tigate ATRX in 2 patients with corticotroph tumors, 1 
nonaggressive macroadenoma and 1 carcinoma, and Lynch 
syndrome, a cancer predisposing syndrome with mutations 
in genes involved in DNA mismatch repair (MLH1, MSH2, 
MSH6, PMS2, EPCAM). Both tumors harbored an MSH2 
mutation, but only the severe case, a carcinoma, in addition 
exhibited an ATRX mutation.
Additional cancer-related mutations were identified and 
associated with ATRX alterations in 8 of 9 cases, TP53 mu-
tations in 6 (3 aggressive corticotroph tumor, 2 corticotroph 
carcinomas, and 1 aggressive lactotroph tumor), PTEN 
mutations in 2, and RB1, NF2, and CDKN2A/B in single 
Figure 2. ATRX deletions in 2 patients with corticotroph carcinoma. (A) Profile of the average amplicon coverage of ATRX coding sequence from 
exon 1 through exon 35. A healthy donor of female origin was included in all NGS experiments (blue). Low amplicon coverage corresponding to de-
letion of ATRX sequence was observed for 2 patients, highlighted with orange and green, respectively. Coverage overviews are shown as inserts. The 
black horizontal bar indicates the position of chromosome X. Arrows mark the deletions in ATRX. (B) Schematic illustration of the 2 large, intragenic 
ATRX deletions spanning exon 2/exon 8 through exon 30. The large exon 9 of ATRX, depicted with stippled lines, is compressed for clarity. (C) 
Diagram of ATRX variants at coding and protein levels, respectively. Definition of ATRX domains were from UniProt. ADD, ATRX-DNMT3-DNMT3L; 
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cases. TP53 mutations have rarely been previously reported 
in pituitary tumors (16). However, recently, TP53 muta-
tions were demonstrated in 6 out of 18 of corticotroph 
USP8 wild-type tumors and correlated with larger tumors 
and higher Ki67 index (35). Our findings, together with 
previous report, may suggest an association of the TP53 
mutations with corticotroph tumors with more aggressive 
phenotype. Findings of multiple mutations in the ATRX 
mutated tumors may indicate genetic instability leading to 
multiple cancer-related genetic events. However, more ex-
tensive molecular genetic analyses are needed to get full in-
sight into genetic landscape of aggressive PitNETs.
The strength of the present study is the well character-
ized cohort of APT and PC and a relatively large number of 
patients, having in mind the rarity of the condition. A limi-
tation is a short follow-up of some of the patients with 
ATRX defects, which limits conclusions on the metastatic 
potential of this mutation.
Although many APT/carcinomas exhibit histological 
features consistent with increased proliferation (Ki-67 
index > 3%, increased mitotic count, and p53 expression) 
(4), and coexistence of 2 of the 3 markers is associated with 
increased risk of tumor progression and recurrence (39), 
the presence of these features does not fully predict future 
aggressive behavior (40, 41). To our knowledge, the present 
findings is the first time that a gene mutation with well-
known oncogenic potential has been consistently reported 
in a proportion of aggressive PitNETs.
Currently, temozolomide is the first-line chemotherapy 
for APT and PC (29). The drug induces an initial response 
rate of 40%, but subsequently most tumors relapse and 
long-term effective alternative therapies are still lacking 
(42). Mutated ATRX is an attractive therapeutic target for 
the subgroup of ATRX negative pituitary tumors. There is 
ongoing intensive research aiming to develop pharmaco-
logical therapies targeting ATRX and ALT (43, 44).
In summary, the results of this study provide a rationale 
for performing ATRX immunohistochemistry as a simple, 
inexpensive, and widely available laboratory test to iden-
tify patients at increased risk for development of highly ag-
gressive and potentially metastatic PitNETs, especially in 
macroadenomas causing Cushing’s disease or in clinically 
silent corticotroph tumors. Patients with pituitary tumors 
harboring an ATRX mutation should be offered closer 
follow-up, including work-up for metastatic dissemination, 
and invasive treatment at the early stages of the disease.
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